APT Therapeutics
uses its expertise in protein engineering to develop optimized human apyrases as an antithrombotic and anti-inflammatory therapy for acute myocardial infarction, stroke, pulmonary arterial hypertension, and transplantation complications.


AstraZeneca acquires antithrombotic from APT Therapeutics

APT Therapeutics today announced a research collaboration, option and asset purchase agreement with AstraZeneca. Under terms of the agreement, AstraZeneca will make an upfront cash payment to APT. APT will be eligible to receive future payments upon achievement of certain key development milestones.

AstraZeneca is a global leader in cardiovascular drug development. By combining their strengths with our own research and development expertise, we have a great opportunity to develop a breakthrough drug that will improve the lives of millions of patients worldwide.
- Ridong Chen, Ph.D. / Founder & CEO, APT Therapeutics.